These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 839097)

  • 21. [Prostatic cancer and its prognosis under Honvan treatment].
    Gaca A; Köhnlein HE; Köttgen H
    Med Welt; 1968 Apr; 15():961-7. PubMed ID: 5717752
    [No Abstract]   [Full Text] [Related]  

  • 22. [Results of combination chemotherapy with etoposide, ifosfamide, peplomycin for advanced prostatic cancer].
    Ushiyama T; Ihara H; Kurita Y; Kageyama S; Ueda D; Mugiya S; Yamaguchi Y; Nakano M; Suzuki K; Kawabe K
    Hinyokika Kiyo; 1993 Dec; 39(12):1139-44. PubMed ID: 8285162
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cholesterol-lowering drugs and advanced prostate cancer incidence in a large U.S. cohort.
    Jacobs EJ; Rodriguez C; Bain EB; Wang Y; Thun MJ; Calle EE
    Cancer Epidemiol Biomarkers Prev; 2007 Nov; 16(11):2213-7. PubMed ID: 17971518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Therapy of prostatic cancer with cyproterone acetate].
    Maier U
    Wien Klin Wochenschr; 1988 Jan; 100(1):16-9. PubMed ID: 2964127
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Cycloplatam in the treatment of patients with disseminated prostatic cancer].
    Matveev BP; Gorbunova VA; Smirnova NB; Zhumagazin ZhD; Bukharkin BV; Orel NF
    Urol Nefrol (Mosk); 1996; (3):34-6. PubMed ID: 8928330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Perspective on "Chemotherapy for advanced prostate cancer: 25 years later": is it a mirage or an oasis?
    Haines IE; Stanley RM
    J Clin Oncol; 2008 Aug; 26(24):4049-50; author reply 4051. PubMed ID: 18711202
    [No Abstract]   [Full Text] [Related]  

  • 27. [Determination of total PSA rate and Gleason score during prostatic cancer in Urologic Hospital Center].
    Diao B; Fall PA; Fall B; Niang L; Diallo Y; Sow Y; Sarr A; Odzébé A; Ndoye AK; Bâ M; Diagne BA
    Dakar Med; 2008; 53(2):111-5. PubMed ID: 19634544
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [A case of advanced prostatic cancer presenting as inguinal mass].
    Ikeda K; Niwa N; Oka F; Ito H; Abe H; Nakagami Y
    Hinyokika Kiyo; 1991 Jul; 37(7):765-7. PubMed ID: 1927782
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Serum testosterone level in patients with advanced prostatic cancer during androgen suppressive treatment].
    Fosså SD; Høst H; Aakvaag A
    Tidsskr Nor Laegeforen; 1981 Oct; 101(28):1570-3. PubMed ID: 7339933
    [No Abstract]   [Full Text] [Related]  

  • 30. Long term therapy with a depot LHRH analogue (Zoladex) in patients with advanced prostatic cancer.
    Denis L; Keuppens F; Mahler C; Debruyne FM; Weil EH; Lunglmayr G; Newling D; Robinson MR; Richards B; Smith PH
    Prog Clin Biol Res; 1987; 243A():221-7. PubMed ID: 2958852
    [No Abstract]   [Full Text] [Related]  

  • 31. [Clinical trial of the systemic chemotherapy for advanced prostatic cancer patients].
    Moriyama M; Nomura S; Miyamoto H; Fukushima S
    Gan To Kagaku Ryoho; 1993 May; 20(7):969-71. PubMed ID: 8489305
    [No Abstract]   [Full Text] [Related]  

  • 32. [Pain relief by high-dose medroxyprogesterone acetate in advanced prostatic cancer].
    Sasagawa I; Satomi S; Umeda K; Katayama T
    Hinyokika Kiyo; 1989 Apr; 35(4):603-8. PubMed ID: 2525316
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Successful treatment of poor prognostic patients with advanced prostatic carcinoma with the association of diethylstilbestrol and cyclophosphamide.
    Germá Lluch JR; Marcuello Gaspar E; de Andrés Basauri L; López Pousa A; López López JJ
    Rev Esp Oncol; 1982; 29(2):317-24. PubMed ID: 7188232
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of locally advanced prostatic carcinoma with LHRH analogues: cytological, DNA-cytophotometrical, and clinical results.
    Borgmann V; al-Abadi H; Nagel R
    Am J Clin Oncol; 1988; 11 Suppl 1():S19-28. PubMed ID: 2968759
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Treatment of prostatic cancer with TAP-144-SR, a depot preparation of LH-RH agonist (leuprolide).
    Isurugi K; Niijima T; Akaza H; Aso Y; Koiso K; Fuse M; Okada K; Usami M; Ohashi T; Ueda T;
    J Chemother; 1989 Jul; 1(4 Suppl):1237-41. PubMed ID: 16312848
    [No Abstract]   [Full Text] [Related]  

  • 36. [Clinical impact of neoadjuvant treatment to radical prostatectomy in locally advanced prostatic cancer].
    Villavicencio H; Laguna P; Ponce de Léon J
    Actas Urol Esp; 1994 May; 18 Suppl():404-8. PubMed ID: 8073926
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The management of clinically localized prostate cancer.
    Natl Inst Health Consens Dev Conf Consens Statement; 1987 Jun 15-17; 6(10):1-6. PubMed ID: 3317009
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of advanced carcinoma of the prostate with Estracyt.
    Nagel R; Kölln CP
    Prog Clin Biol Res; 1976; 6():267-84. PubMed ID: 1023214
    [No Abstract]   [Full Text] [Related]  

  • 39. [Prostatic cancer developing after transurethral resection of the prostate for benign prostatic hyperplasia].
    Tanaka Y; Aoyama H; Momose H; Ono T; Samma S; Tanaka N; Akiyama T; Tani Y; Masuda Y; Matsuki H; Tani M; Tanaka M
    Hinyokika Kiyo; 2001 Jan; 47(1):11-4. PubMed ID: 11235214
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diagnosing leptomeningeal carcinomatosis with negative CSF cytology in advanced prostate cancer.
    Bernstein WB; Kemp JD; Kim GS; Johnson VV
    J Clin Oncol; 2008 Jul; 26(19):3281-4. PubMed ID: 18591564
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.